3rd Aug 2009 07:00
|
For immediate release |
3 August 2009 |
ALLIANCE PHARMA PLC
("Alliance" or "the Company")
Notification of Interim Results
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2009 on Wednesday 9 September 2009.
A briefing for analysts will be held at 10.00am on the day of the results at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
For further information:
|
Alliance Pharma plc
|
+ 44 (0) 1249 466966
|
|
John Dawson, Chief Executive
|
|
|
Richard Wright, Finance Director
|
|
|
www.alliancepharma.co.uk
|
|
|
|
|
|
Buchanan Communications
|
+ 44 (0) 20 7466 5000
|
|
Mark Court / Rebecca Skye Dietrich / Stasa Filiplic
|
|
|
|
|
|
Numis Securities Limited
|
+ 44 (0) 20 7260 1000
|
|
Nominated Adviser: Michael Meade / Brent Nabbs
|
|
|
Corporate Broking: David Poutney
|
|
Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or licenses, the rights to 35 branded pharmaceutical products and continues to explore opportunities to expand the range.
Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in the treatment of dermatological conditions, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Related Shares:
Alliance Pharma